University of Virginia Patent Foundation

Chinghai Kao

Song-Chu Ko

Robert A Sikes

Jun Cheon

Leland W K Chung

Leland W Chung

Thomas A Gardner

A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

Utilization of osteocalcin promoter to deliver therapeutic genes to tumors

The present invention relates to methods for the production of high titers of serum-free lytic viruses in a hollow fiber cartridge capillary system. The invention further relates to methods of infecting target cells at high multiplicity and for producing high concentrations of transduced target cells.

Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system

In vivo suppression of osteosarcoma pulmonary metastasis with

A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, to Ad-OC-TK resulted in the induction of osteoblast-specific cell death in vitro. The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.

Osteocalcin promoter-based toxic gene therapy for the treatment of

Growing community of inventors

Charlottesville, VA, United States of America

Chinghai Kao